-
Previous research failed to show that the angiotensin II antagonist losartan at 50 mg per day was as effective as captopril in reducing mortality in patients with heart failure after myocardial infarction. This raised the question of whether this new class of drugs may be substituted for ACE inhibitors in treating these high-risk patients.
-
The rhythm strip shown in the Figure was obtained from a middle-aged man in severe pain from a musculoskeletal disorder. He was not having chest pain, and had no known history of cardiovascular disease. He had an episode of vomiting shortly before this tracing was recorded. Is there evidence of heart block? If so, what type?
-
A topical estradiol emulsion has been approved for treating symptoms of menopause. Currently available estrogen products include pills, patches, and vaginal rings. The new estrogen emulsion provides another option for estrogen therapy. Novavax Inc markets this topical formulation as Estrasorb.
-
Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery.
-
A standardized withdrawal-of-life-support order form was viewed as helpful by physicians and nurses and changed medication delivery in a positive manner.
-
In a randomized, clinical trial involving patients with ALI/ARDS from non-sepsis etiologies, inhaled nitric oxide at 5 ppm failed to improve any of the clinically meaningful outcomes.
-
The first head-to-head comparison study of an ACE inhibitor and an angiotensin receptor blocker, to assess renoprotective effects in type 2 diabetes, has shown that the drugs are comparable in their benefit.
-
The consecutive rhythm strips seen in the Figure were obtained from a 73-year-old man with a history of ischemic cardiomyopathy. QRS widening is the result of underlying bundle branch block. In view of the atrial activity seen in these rhythm strips, what would you want to ask the patient?
-
In an attempt to clarify the role of early intensive glycemic control, newly diagnosed type 2 diabetes patients were treated with insulin by means of an insulin pump on an inpatient basis for two weeks, after which they were discharged.
-
A new non-aluminum, non-calcium, phosphate binder has been approved by the FDA.
